Pharvaris (PHVS) Assets Average (2021 - 2026)
Pharvaris' (PHVS) quarterly Assets Average came in at $327.5 million in Q1 2026, up 14.46% YoY from $286.1 million in Q1 2025, and down 12.32% on a QoQ basis from $373.5 million in Q4 2025.
Pharvaris (PHVS) Assets Average (2021 - 2026) Analysis & Trends
Pharvaris (PHVS) has 6 years of Assets Average data on file, last reported at $327.5 million in Q1 2026.
- Quarterly Assets Average rose 14.46% year-over-year to $327.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $327.5 million (up 14.46% YoY) and the FY2025 annual result came in at $328.0 million, down 12.15% from the prior year.
- Assets Average fell to $327.5 million in Q1 2026, from $373.5 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $419.6 million in Q1 2024 to a low of $164.9 million in Q1 2023.
- A 5-year average of $280.2 million and a median of $286.1 million in 2025 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average soared 154.47% — and 2025, when it plunged 36.84%.
- Tracing PHVS's Assets Average over 5 years: stood at $187.9 million in 2022, then jumped by 63.21% to $306.7 million in 2023, then rose by 6.85% to $327.6 million in 2024, then increased by 14.01% to $373.5 million in 2025, then fell by 12.32% to $327.5 million in 2026.
- The last three Assets Average figures came in at $327.5 million (Q1 2026), $373.5 million (Q4 2025), and $316.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - | 343.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 343.09 Mn |
| Mar 31, 2026 | 327.53 Mn |
| Dec 31, 2025 | 373.55 Mn |
| Sep 30, 2025 | 316.84 Mn |
| Jun 30, 2025 | 249.22 Mn |
| Mar 31, 2025 | 286.15 Mn |
| Dec 31, 2024 | 327.65 Mn |
| Sep 30, 2024 | 361.42 Mn |
| Jun 30, 2024 | 394.55 Mn |
| Mar 31, 2024 | 419.59 Mn |
| Dec 31, 2023 | 306.66 Mn |
| Sep 30, 2023 | 195.48 Mn |
| Jun 30, 2023 | 182.63 Mn |
| Mar 31, 2023 | 164.88 Mn |
| Dec 31, 2022 | 187.90 Mn |
| Sep 30, 2022 | 212.63 Mn |
| Jun 30, 2022 | 223.17 Mn |
| Mar 31, 2022 | 234.18 Mn |
| Dec 31, 2021 | 252.86 Mn |
| Sep 30, 2021 | 269.87 Mn |